Cancer Prevention and Control
Leukemia, Lymphoma, and Myeloma Program
Bone Marrow and Stem Cell Transplantation Program
Area of Interest
I am a hematologist and oncologist with a clinical focus in blood cancers. Research interests include novel strategies to measure and intervene upon physical function during and after cancer treatment. Digital biomarker development, physiologic sensor integration, home-based functional assessments, patient reported outcomes implementation, and health coaching are areas of current efforts. A major goal is to leverage emerging technologies to improve the cancer patient experience.
I have also assisted the American Society of Hematology, the Center for International Blood and Marrow Transplant Research, and others in work involving large registries to develop risk modeling for clinical outcomes in patients with hematologic conditions.
Awards and Honors
- Clinical Research Training Institute participant, American Society of Hematology, 2010
- Cambridge/Somerville Pediatric Resident Teaching Award, Massachusetts General Hospital for Children, 2006
- Thomas Jefferson Award, Duke University School Of Medicine, 2003
- AMA Foundation Leadership Award, 2002
- Eugene A. Stead Student Research Scholarship, Duke Medical School, 2001
- Secretary’s Award for Distinguished Service, United States Department of Health and Human Services, 1998
News and Stories
Cancer and Aging Research Symposium highlights latest findings, promotes collaboration
The symposium drew together experts from academia and industry to share laboratory and clinical research focused on the diagnosis and treatment of cancer and survivorship care for older adults.
Five questions with UNC Lineberger’s William Wood
William Wood, MD, MPH, is a national leader in the digital health field, and is motivated by a desire to understand the patient experience in order to ultimately improve it.
Study reveals communication gap between women, doctors about breast cancer treatment symptoms
Kirsten Nyrop, PhD, Hyman Muss, MD, and colleagues compared how women with breast cancer rated the severity of 17 of their own symptoms with physician ratings of chemotherapy toxicity.